Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is KemPharm Inc (KMPH) A Good Stock To Buy?

Page 1 of 2

The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review of these public filings is finally over, so this article is set to reveal the smart money sentiment towards KemPharm Inc (NASDAQ:KMPH).

KemPharm Inc (NASDAQ:KMPH) shares didn’t see a lot of action during the third quarter. Overall, hedge fund sentiment was flat over the quarter. The stock was in 6 hedge funds’ portfolios at the end September. At the end of this article we will also compare KMPH to other stocks including Profire Energy, Inc. (NASDAQ:PFIE), Tenax Therapeutics Inc (NASDAQ:TENX), and OHA Investment Corp (NASDAQ:OHAI) to get a better sense of its popularity.

Follow Kempharm Inc (NASDAQ:KMPH)
Trade (NASDAQ:KMPH) Now!

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

test, cancer, researcher, research, dna, bio, clean, modern, chemistry, human, white, medical, sample, pipette, life, culture, laboratory, biotechnology, genetic, disease,

science photo/Shutterstock.com

Keeping this in mind, let’s take a look at the latest action surrounding KemPharm Inc (NASDAQ:KMPH).

What does the smart money think about KemPharm Inc (NASDAQ:KMPH)?

At Q3’s end, a total of 6 of the hedge funds tracked by Insider Monkey were long this stock, unchanged from the second quarter of 2016. On the other hand, there were a total of 7 hedge funds with a bullish position in KMPH at the beginning of this year. So, let’s see which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

KMPH Chart

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, James E. Flynn’s Deerfield Management has the most valuable position in KemPharm Inc (NASDAQ:KMPH), worth close to $4.9 million, amounting to 0.2% of its total 13F portfolio. The second most bullish fund manager is Alyeska Investment Group, led by Anand Parekh, holding a $4.3 million position; less than 0.1% of its 13F portfolio is allocated to the company. Other hedge funds and institutional investors that are bullish include Steve Cohen’s Point72 Asset Management, Mark Kingdon’s Kingdon Capital and Richard Driehaus’s Driehaus Capital. We should note that none of these hedge funds are among our list of the 100 best performing hedge funds which is based on the performance of their 13F long positions in non-microcap stocks.

Page 1 of 2